Approval · Notice of Compliance 14845 · 2013
ABBOTT-CLOPIDOGREL: Notice of Compliance 14845
Issued October 22, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14845
- Date
- October 22, 2013
- Company
- Abbott Laboratories Co.Saint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Therapeutic class
- Platelet aggregation inhibitor
- Canadian reference product
- PLAVIX (Sanofi-Aventis Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ABBOTT-CLOPIDOGREL | 02412942 | Cancelled Post Market |
Medicinal ingredients
- CLOPIDOGREL BISULFATE 75 MG per TAB